Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, we have relatively little data on the use of these newer atypical agents in breastfeeding women.
The newer “atypical” or second-generation antipsychotic agents are now used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders. The National Pregnancy Registry for Atypical Antipsychotics [...]
Women with bipolar disorder are at a higher risk for relapse during pregnancy and that the risk is even higher during the postpartum period. In addition, women with bipolar disorder are more vulnerable to postpartum [...]
The use of the newer “atypical” or second-generation antipsychotic agents continues to increase. These medications are used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and anxiety disorders. Although [...]
For women with premenstrual dysphoric disorder (PMDD), selective serotonin reuptake inhibitors (SSRIs) are the first line of pharmacological treatment. A significant body of evidence, including numerous double-blind, randomized studies, supports the effectiveness of SSRIs in [...]
Given the number of younger women using atypical antipsychotic medications, we need more accurate data regarding the reproductive safety of these medications. To better understand the link between antipsychotic medication and medical conditions associated with [...]
Second-generation or “atypical” antipsychotics, such as olanzapine (Zyprexa), aripiprazole (Abilify), and risperidone (Risperdal), are used far more frequently than are the first-generation or “typical” antipsychotics, such as haloperidol (Haldol). This is largely because the newer [...]
This is the second part of a two part series on the use of antipsychotic medications during pregnancy. Read Part 1 here, which reviews data from the Australian antipsychotic registry.
Despite the use of the newer “atypical” antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, three is relatively little data on the reproductive safety of these newer atypical agents.
Since their introduction in the 1990s, atypical (second-generation) antipsychotics have replaced typical (first generation) antipsychotics as the first-line treatment for schizophrenia and related psychotic disorders. These drugs are widely used by reproductive age women across many other disease states including bipolar disorder, major depression and anxiety disorders as either primary or adjunctive treatments.
